InvestorsHub Logo
Followers 3
Posts 205
Boards Moderated 0
Alias Born 06/21/2020

Re: Threeflight post# 35351

Friday, 03/31/2023 7:09:01 PM

Friday, March 31, 2023 7:09:01 PM

Post# of 36558
This has been my contention on how the trial and data review has gone.

I certainly acknowledge that Revive has to own a bit of the process. But it is clear that the FDA gets to play king maker. They can control the tempo of the trial, move the target just enough so that the little guys struggle to change course, add a little more to what is required in testing, etc...

Throughout Revive's course we would receive the occasional update that the FDA was going to hand hold them to and through the next phase. But the timelines that we would be given was something crazy like 3-4 months at a time. When that time would lapse, the landscape would have changed just enough that we could see relevancy slipping.

We may never know all of what was truly behind it. Very likely some dropped balls on Revive's part. But in the meantime, the big's were basically being fast tracked left and right, only months or years later to learn that corners were cut in testing, or in some cases data was falsified (bad or damning data was intentionally left out), and they floated through unchecked.

Maybe there is hope yet. But I think most of us now understand that the FDA doesn't truly have the publics best interest at hand.